Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.56 |
| ▸ | NCF1 | P14598 | 14/20 | 0.51 |
| ▸ | CYBB | P04839 | 5/20 | 0.50 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471667 | 0.85 | BACE1 (0.53) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL13349519 | 0.81 | MAOA (0.42) | BACE1KDM4EALDH1A1GLAMAOA | |
| SCHEMBL17433995 | 0.81 | BACE1 (0.61) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL13349520 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1GLACHRM2ADRA2A | |
| SCHEMBL832149 | 0.78 | BACE1 (0.58) | BACE1NCF1KDM4EALDH1A1GLA | |
| SCHEMBL28319501 | 0.77 | DCPS (0.43) | KDM4EALDH1A1GLACHRM2ADRA2A | |
| SCHEMBL17433997 | 0.77 | BACE1 (0.51) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL1133378 | 0.76 | BACE1 (0.60) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL3431601 | 0.75 | BACE1 (0.64) | BACE1NCF1CYBBNOX5NOS2 | |
| SCHEMBL29769305 | 0.75 | BACE1 (0.64) | BACE1NCF1CYBBNOX5NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2975037-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975037-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | PDE10A, PDE5A, PDE3B | BACE1 1405/4885NCF1 2031/4885CYBB 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.